The collaboration will offer people an opportunity to learn about and potentially participate in a Phase III clinical trial within Walgreens pharmacies.
The updated label with additional data reinforces the safety and efficacy profile of Biktarvy to treat pregnant people with HIV-1 with suppressed viral loads, the company said.